May 2023 Latest News Round-up
April was a busy month for the Small Pharma team, from new journal publications to panels and conference presentations. Read on for the highlights of the month.
We published a paper on the pharmacokinetics of DMT in humans
We’re proud to announce the publication of our new scientific paper: Pharmacokinetics of N,N-dimethyltryptamine in Humans, published in the European Journal of Drug Metabolism and Pharmacokinetics. Based on data from our SPL026 Phase I clinical trial, this is the first study to our knowledge to determine the full pharmacokinetic profile and parameters of DMT in humans.
We believe our findings contribute to the development of improved pharmacokinetic and metabolic models of DMT, and to the design of intravenous infusion regimens for the treatment of mental health conditions.
You can access the full paper here.
Our Head of IP presented on a panel at the IAM Live: IP and Emerging Technology Europe Conference
Our Head of IP, Emma Hodge, presented on a panel at the IAM: Live IP and Emerging Technology Europe conference in London. The Masterclass panel focused on the topic ‘What does collaboration mean for your IP strategy?”
Alongside a line up of cross-industry intellectual property experts, a wide range of topics were discussed including drafting and negotiating collaboration agreements, differences in jurisdictions, and managing relationships across industry sectors.
Our SPL026 Phase IIa data was presented at Breaking Convention, Europe’s largest psychedelics conference
Held over three days at the University of Exeter, we heard from academics and researchers at the cutting edge of psychedelic research, who shared the latest insights on topics ranging from therapy to drug policy and theories of consciousness to AI.
Chief Investigator of our SPL026 Phase IIa clinical trial Dr. David Erritzoe from Imperial College London shared data from the trial in his talk on psychedelic treatments for depression.
The agenda was wide-ranging and diverse, which made for lively discussion and debate as experts from multiple disciplines came together to share insights, ideas and pose questions. The conference was a great reminder of all the important work taking place to advance the future of psychedelic therapy as a potential clinical treatment.
We presented preclinical SPL028 data at the BNA Festival of Neuroscience Conference
Last week, our Research Manager Meghan Good delivered a poster presentation at the International BNA Festival of Neuroscience Conference in Brighton. The poster showcased preclinical data from our research into SPL028, our proprietary deuterated derivative of DMT.
Our preclinical studies suggest that SPL028 offers a similar safety and pharmacological profile to our lead candidate SPL026 or DMT, while being differentiated by its pharmacokinetics.
Our aim is to deliver a treatment with an extended psychedelic experience in comparison to 20-25 minutes with SPL026, but still significantly shorter than the experience of other psychedelics, such as psilocybin and lysergic acid diethylamide (LSD). You can access the poster here.
We are currently running a first-in-human Phase I clinical trial with SPL028, comparing two routes of administration – intravenous and intramuscular. The trial is progressing on track and we look forward to sharing results in the coming months.
Next week, we’ll be in Montreal presenting at the CINP World Congress of Neuropsychopharmacology
If you’re heading to the CINP conference in Montreal next week (7-10 May), our Chief Medical and Scientific Officer Dr. Carol Routledge will be delivering a poster presentation on the positive data from our Phase IIa trial of SPL026 in patients with Major Depressive Disorder. The presentation details are:
Date: Monday May 8, 2023
Time: 10:15 – 10:45 a.m. and 4:00 – 4:30 p.m. (EDT)
Location: Level 2 Foyer, Fairmont The Queen Elizabeth Hotel, Montreal, Canada